Merck Issues Statement on Granting of Coordinated Pre-Trial Status For Federal VIOXX(reg) Lawsuits

The federal Judicial Panel on Multidistrict Litigation granted motions by several parties, including Merck, to transfer
all VIOXX(reg) shareholder suits pending in federal courts nationwide into one consolidated Multidistrict Litigation (MDL) for
coordinated pre-trial proceedings.


The shareholder cases, now designated as "MDL 1658-In re Merck & Co., Inc., Securities, Derivative & 'ERISA' Litigation,"
include all federal securities, shareholder derivative and ERISA actions. Those cases are now being transferred to the
United States District Court for New Jersey before District Judge Stanley Chesler.


Previously, on Feb. 16, the federal Judicial Panel on Multidistrict Litigation granted motions to transfer all VIOXX product
liability lawsuits pending in federal courts nationwide to the Eastern District Court of Louisiana before District Judge
Eldon E. Fallon for coordinated pre-trial proceedings. Those cases have been designated as "MDL 1657-In re VIOXX Product
Liability Litigation."


With respect to the shareholder cases, designated as "MDL1658-In re Merck & Co., Inc., Securities, Derivative & 'ERISA'
Litigation," Judge Chesler will now set the schedule for pre-trial matters.


About Merck


Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in
1891, Merck discovers, develops, manufactures and markets vaccines and medicines in more than 20 therapeutic categories. The
company also devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate
Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a
not-for-profit service. For more information, visit merck.



Forward-Looking Statement


This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements regarding product development, product
potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially
from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result
of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements
in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2003, and in its periodic reports on Form 10-Q and Form 8-K, which
the company incorporates by reference.


merck/newsroom


View drug information on Vioxx.